# US 2026/0085098 A1 · Method for the treatment of an acute respiratory distress syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085098 A1
- Document ID: US20260085098A1
- Status: Published application
- Kind: A1
- Application number: 19/207,227
- Filed: 2025-05-13
- Published: 2026-03-26
- Earliest claimed: 2017-01-12
- Assignees: Revolo Biotherapeutics Limited
- Applicants: Revolo Biotherapeutics Limited
- Inventors: Andrew Lightfoot; Nicola Cooper; Donata Federici Canova; Roly Foulkes
- Web page: https://patentgrep.com/patent/US20260085098A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 14/35: from Mycobacteriaceae (F)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.

## Claims

### Claim 1

A method for acute treatment of an acute respiratory distress syndrome (ARDS) associated with a respiratory infection, the method comprising the steps of:
(a) administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule, the peptide molecule comprising an amino acid sequence as set forth in SEQ ID NO: 1, or having more than 95% identity to the amino acid sequence as set forth in SEQ ID NO: 1, wherein the acute treatment method causes remission of the ARDS in the subject; and
(b) stopping the administration of the peptide molecule upon remission of the ARDS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide molecule is less than 50 amino acid residues in length.

### Claim 3 (depends on 1)

The method of claim 1, wherein the peptide molecule is less than 40 amino acid residues in length.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide molecule consists of the amino acid sequence of SEQ ID NO: 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein remission comprises reduction, alleviation or one or more symptoms of the ARDS.

### Claim 6 (depends on 5)

The method of claim 5, wherein the one or more symptom of the ARDS is selected from the group consisting of: low blood oxygen, labored and unusually rapid breathing, clicking, bubbling, or rattling sounds in the lungs when breathing, low blood pressure, and extreme tiredness.

### Claim 7 (depends on 1)

The method of claim 1, wherein the remission comprises reduction, alleviation or elimination of one or more symptoms of the ARDS for a period of time which significantly exceeds a plasma pharmacokinetic half-life of the peptide molecule.

### Claim 8 (depends on 1)

The method of claim 1, wherein the remission is maintained when a plasma concentration of the peptide molecule is below a lower limit of quantification.

### Claim 9 (depends on 1)

The method of claim 1, wherein the remission comprises a significant decrease in the amount of one or more inflammatory marker such as a cytokine or a chemokine in the subject relative to a control subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the one or more inflammatory marker are selected from the group consisting of: TNF-α, IFN-γ, IL-1γ, IL-6, KC/IL-8, IL-10, IL-17, MCP-1, MIP-1α, MIP-3α, G-CSF, and GM-CSF.

### Claim 11 (depends on 1)

The method of claim 1, wherein the respiratory infection is caused by a pathogen selected from the group consisting of: a viral pathogen, a bacterial pathogen, a fungal pathogen, and parasitic pathogen.

### Claim 12 (depends on 11)

The method of claim 11, wherein the viral pathogen is selected from the group consisting of: Influenza A, H1N1, H5N1, H7N9, severe acute respiratory syndrome (SARS), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and Middle East Respiratory Syndrome (MERS).

### Claim 13 (depends on 11)

The method of claim 11, wherein the bacterial pathogen is selected from the group consisting of: Streptococcus pneumoniae, Staphylococcus aureus, Legionella pneumophila, Pneumocystis jirovecii, and an enteric gram-negative organism.

### Claim 14 (depends on 1)

The method of claim 1, wherein the respiratory infection is a hospital-acquired pneumonia (HAP) caused by a pathogen selected from the group consisting of: Influenza A, Respiratory Syncytial Virus (RSV), human metapneumovirus (hMPV), and a human parainfluenza virus (HPIV) selected from HPIV-1, HPIV-2, HPIV-3, HPIV-4a and HPIV-4b.

### Claim 15 (depends on 1)

The method of claim 1, wherein the respiratory infection is caused by Influenza A.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is further administered one or more additional therapeutic agents.

### Claim 17 (depends on 16)

The method of claim 16, wherein the one or more therapeutic agents is selected from the group consisting of disease modifying agents, analgesics, anti-inflammatory agents, anti-allergic drugs, allergen immunotherapeutic agents, antivirals, antibiotics, antibodies and steroids.

### Claim 18 (depends on 8)

The method of claim 8, wherein the plasma concentration is below the lower limit of quantification at circulating levels of less than 20 ng/ml.

### Claim 19 (depends on 1)

The method of claim 1, wherein remission of the ARDS is for a period of at least 7 days after administration of a final dose of the peptide molecule.

### Claim 20 (depends on 1)

The method of claim 1, wherein remission of the ARDS is for a period of at least 14 days after administration of a final dose of the peptide molecule.
